Autotransplantation

Global Autologous Matrix-Induced Chondrogenesis (AMIC) Strategic Industry Report 2024: Market to Reach $278 Million by 2030 - Growing Demand for Minimally-Invasive Surgeries to Propel Market Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 29, 2024

The "Autologous Matrix-Induced Chondrogenesis (AMIC) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Autologous Matrix-Induced Chondrogenesis (AMIC) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Autologous Matrix-Induced Chondrogenesis (AMIC) estimated at US$153 Million in the year 2022, is projected to reach a revised size of US$278 Million by 2030, growing at a CAGR of 7.7% over the analysis period 2022-2030.
  • Collagen, one of the segments analyzed in the report, is projected to record a 7.5% CAGR and reach US$158.8 Million by the end of the analysis period.
  • The Autologous Matrix-Induced Chondrogenesis (AMIC) market is poised for growth due to the increasing prevalence of joint disorders.

Orphan designation: Autologous CD34+ haematopoietic stem and progenitor cells transduced with a lentiviral vector encoding the interferon alpha-2 gene Treatment of glioma, 20/06/2023 Positive

Retrieved on: 
Sunday, February 4, 2024

Key facts

Key Points: 
  • Key facts
    - Active substance
    - Autologous CD34+ haematopoietic stem and progenitor cells transduced with a lentiviral vector encoding the interferon alpha-2 gene
    - Intended use
    - Treatment of glioma
    - Orphan designation status
    - Positive
    - EU designation number
    - EU/3/23/2794
    - Date of designation
    - Sponsor
    Genenta Science S.p.A.
  • Patients' organisations
    For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
    European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:
    EMA list of opinions on orphan medicinal product designation
    EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:

IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting

Retrieved on: 
Friday, November 10, 2023

NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that the Company will present two posters at the Society for Neuro-Oncology (SNO) 28th Annual Meeting, taking place November 15-19, 2023, in Vancouver, British Columbia. The posters highlight the potential of IN8bio’s DeltEx Drug Resistant Immunotherapy (DRI), genetically modified and chemotherapy-resistant gamma-delta T cells to treat patients with newly diagnosed glioblastoma multiforme (GBM). The first poster is a TIPs poster detailing the study design for INB-400, the company-sponsored Phase 2 trial and the second will be a “late-breaker” poster providing updated clinical data from the Phase 1 INB-200 trial.

Key Points: 
  • The posters highlight the potential of IN8bio’s DeltEx Drug Resistant Immunotherapy (DRI), genetically modified and chemotherapy-resistant gamma-delta T cells to treat patients with newly diagnosed glioblastoma multiforme (GBM).
  • “We are encouraged by the safety and preliminary efficacy signal we have seen in our Phase 1 trial treating GBM patients with autologous, genetically modified gamma-delta T cells.
  • The University of Louisville and The Cleveland Clinic are the first clinical sites activated to enroll patients.
  • GBM remains a disease with significant unmet need, with limited treatment options and poor associated outcomes.

XNK Therapeutics announces poster presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Retrieved on: 
Monday, November 6, 2023

Two abstracts have been accepted for presentation at the meeting.

Key Points: 
  • Two abstracts have been accepted for presentation at the meeting.
  • The first poster, titled Harnessing the Potential of Autologous NK Cells for Immune Therapy of Patients with Advanced Bladder Cancer, describes the successful expansion of autologous NK cells from peripheral blood mononuclear cells (PBMCs) from bladder cancer patients.
  • XNK will be represented at the meeting by Chief Scientific Officer Dr. Anna-Karin Maltais.
  • Naval Daver at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA, for the AML abstract.

XNK Therapeutics announces poster presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Retrieved on: 
Monday, November 6, 2023

Two abstracts have been accepted for presentation at the meeting.

Key Points: 
  • Two abstracts have been accepted for presentation at the meeting.
  • The first poster, titled Harnessing the Potential of Autologous NK Cells for Immune Therapy of Patients with Advanced Bladder Cancer, describes the successful expansion of autologous NK cells from peripheral blood mononuclear cells (PBMCs) from bladder cancer patients.
  • XNK will be represented at the meeting by Chief Scientific Officer Dr. Anna-Karin Maltais.
  • Naval Daver at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA, for the AML abstract.

Anixa Biosciences to Present at the Ovarian Cancer Research Alliance (OCRA) Ovarian Cancer National Conference

Retrieved on: 
Tuesday, October 31, 2023

SAN JOSE, Calif., Oct. 31, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will present at the Ovarian Cancer National Conference taking place from November 1 – 3, 2023.

Key Points: 
  • "We are pleased to be presenting at the Ovarian Cancer National Conference," said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences.
  • "We look forward to providing an overview of our Phase 1 ovarian cancer trial to an audience which is highly interested in new therapies to battle ovarian cancer."
  • The Ovarian Cancer National Conference is organized by the Ovarian Cancer Research Alliance ("OCRA").
  • The organization has invested $100 million in ovarian cancer research, educated 95,000 medical professionals, and advocated for $200 million in government research and education funding.

Paradigm Completes 40,000th Procedure with the QUICKDRAW MIS Bone Harvester.

Retrieved on: 
Wednesday, October 11, 2023

Paradigm BioDevices, “The Leader in MIS Bone Graft Harvesting,” is pleased to announce the completion of 40,000 procedures utilizing the QUICKDRAW MIS Bone Grafting System.

Key Points: 
  • Paradigm BioDevices, “The Leader in MIS Bone Graft Harvesting,” is pleased to announce the completion of 40,000 procedures utilizing the QUICKDRAW MIS Bone Grafting System.
  • QuickDraw is a percutaneous or MIS bone grafting system developed to address risk factors associated with iliac crest bone grafting.
  • Paradigm will be exhibiting QuickDraw at the North American Spine Society Booth #1617 on October 18-20th.
  • QuickDraw MIS Bone Harvester is a company trademark.

Cartesian Therapeutics Announces Landmark Study in The Lancet Neurology of First Successful Clinical Trial of RNA Cell Therapy in Autoimmunity

Retrieved on: 
Thursday, June 22, 2023

Cartesian Therapeutics , a clinical-stage biotechnology company pioneering cell therapies for autoimmune diseases, announced today the publication of a landmark paper in The Lancet Neurology.

Key Points: 
  • Cartesian Therapeutics , a clinical-stage biotechnology company pioneering cell therapies for autoimmune diseases, announced today the publication of a landmark paper in The Lancet Neurology.
  • The study describes Descartes-08, a cutting-edge RNA CAR-T (rCAR-T) therapy administered to patients with generalized myasthenia gravis (MG), a debilitating autoimmune neurological disease.
  • This is the first clinical trial using rCAR-T to treat autoimmunity, and the first successful Phase 2 trial using an engineered cell therapy to treat autoimmunity.
  • Clinical benefit was sustained long-term for most patients, even months after completing the course of therapy.

ImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with Leucid Bio

Retrieved on: 
Wednesday, April 12, 2023

Under the terms of the agreement, ImaginAb will license and supply clinical doses of ImaginAb's investigational CD8 ImmunoPET tracer, 89Zr crefmirlimab berdoxam, to Leucid for use in its basket study in solid tumors, with LEU011 targeting NKG2DL, Autologous CAR T-cells.

Key Points: 
  • Under the terms of the agreement, ImaginAb will license and supply clinical doses of ImaginAb's investigational CD8 ImmunoPET tracer, 89Zr crefmirlimab berdoxam, to Leucid for use in its basket study in solid tumors, with LEU011 targeting NKG2DL, Autologous CAR T-cells.
  • Ian Wilson, Chief Executive Officer of ImaginAb, said: "We are delighted that Leucid Bio will use our investigational CD8 ImmunoPET for the first time in conjunction with CAR-T therapies.
  • This agreement with Leucid Bio is an opportunity for ImaginAb to continue expanding our partnerships and showcases the increasing adoption of our CD8 ImmunoPET technology."
  • Artin Moussavi, Chief Business Officer of Leucid Bio, commented: "This is an exciting partnership for Leucid as this cutting edge technology will provide evidence of the biodistribution of LEU011 CAR T-cells.

Creative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business Update

Retrieved on: 
Tuesday, April 4, 2023

PHOENIX, April 4, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company" or "We") (NASDAQ: CELZ), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced the filing of its Form 10-K on March 31, 2023 for the year ended December 31, 2022 (FY 2022) and provided a summary of the progress made in 2022 and thus far in 2023.

Key Points: 
  • PHOENIX, April 4, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company" or "We") (NASDAQ: CELZ), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced the filing of its Form 10-K on March 31, 2023 for the year ended December 31, 2022 (FY 2022) and provided a summary of the progress made in 2022 and thus far in 2023.
  • "2022 was a year of significant clinical, regulatory, and partnership milestones, and our efforts in these areas have continued in earnest during 2023," said Timothy Warbington, Chief Executive Officer of Creative Medical Technology.
  • Two-Year Follow Up Data for Autologous OvaStem™: in Q3 2022, we announced positive two-year follow up data for the OvaStem® pilot study.
  • CaverStem®: in Q2 2022, we presented our CaverStem® program at the American Urological Association Annual Meeting in New Orleans.